1427404-87-2

Basic information

• Product Name: 4-Bromo-pyrazolo[1,5-a]pyridine
• Synonyms: 4-Bromo-pyrazolo[1,5-a]pyridine
• CAS NO: 1427404-87-2
• Molecular Formula: C7H5BrN2
• Molecular Weight: 197.032
• EINECS: -0
• Mol File: 1427404-87-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.69±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 1.52±0.30(Predicted)
• CAS DataBase Reference: 4-Bromo-pyrazolo[1,5-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-pyrazolo[1,5-a]pyridine(1427404-87-2)
• EPA Substance Registry System: 4-Bromo-pyrazolo[1,5-a]pyridine(1427404-87-2)

Safety Data

• Hazardous Substances Data: 1427404-87-2(Hazardous Substances Data)

Usage

General Description

4-Bromo-pyrazolo[1,5-a]pyridine is a chemical compound with the molecular formula C6H4BrN3. It is a heterocyclic compound that is used in pharmaceutical research and development. It is known to have potential therapeutic applications due to its ability to interact with certain biological receptors. The chemical structure of 4-Bromo-pyrazolo[1,5-a]pyridine makes it a valuable building block for the synthesis of new drug candidates. Its unique structure and reactivity make it a key component in the exploration of new chemical entities for various medical and therapeutic applications.

Upstream product

• 55899-29-1 ethyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate 
• 626-55-1 3-Bromopyridine 
• 1062368-71-1 methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate 

Relevant articles and documents

Pyrimidine-4 (3H)-ketone heterocyclic compound, preparation method thereof and application of pyrimidine-4 (3H)-ketone heterocyclic compound in medicine

The invention relates to pyrimidine-4 (3H)-ketone heterocyclic compounds suitable for inhibiting or regulating SHP2, a preparation method of the pyrimidine-4 (3H)-ketone heterocyclic compounds and application of the pyrimidine-4 (3H)-ketone heterocyclic compounds in medicine. Specifically, the invention relates to a compound as shown in a general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing related diseases mediated by SHP2, especially cancers by using the compound or the pharmaceutically acceptable salt thereof, and a preparation method of the compound or the pharmaceutically acceptable salt thereof. The invention also relates to application of the compound or the pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing SHP2-mediated related diseases. Wherein each substituent in the general formula (I) is as defined in the specification.